AN FRANCISCO — It’s hard to remember amid all the cocktail parties, panel sessions, networking meetings, and general glad-handing, but there’s an actual health care investor conference at the heart of the biotech industry’s gathering here each January.

Thousands of people flock to the J.P. Morgan Healthcare Conference but never actually step inside the conference’s home base at the Westin St. Francis Hotel on the western side of Union Square. They’re off doing other biotechy things. But about 9,000 people — executives from 450 biotech and drug companies plus investors and ne’er-do-wells like, ahem, journalists — do actually attend the conference.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • For Gilead, I hope someone would ask John Milligan for the status of Hrvoni and Epclusa approval and launch in china, when would Ovladi get on the country and regional lists, and what are the projections for revenue for all three drugs in 2018. Finally what about GLPG acquisitions in 2018.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.